Boehringer Ingelheim

New technologies are opening up mental health services to previously overbooked and underserved populations.

Mental Health Tech

<div>
 
 Click Therapeutics develops software that provides prescription digital therapeutics (PDTs) for individuals diagnosed with mental health and chronic conditions. Its only nonprescription therapeutic, a smoking cessation product called Ckickotine, is commercially available and clinically validated despite not requiring FDA approval. The company also has eight PDTs in the pipeline across a variety of therapeutic areas that are still in the development stage including Major Depressive Disorder (MDD), insomnia, schizophrenia, migraines, acute coronary syndrome, overactive bladder, obesity, and chronic lower back pain. Its PDT for MDD is in Phase III pivotal trials as of March 2022. The company leverages adaptive data science and machine learning algorithms to personalize content and ensure user engagement. Click&rsquo;s programs attempt to change individual behavior through cognitive and neurobehavioral mechanisms and can be used independently or in conjunction with biomedical treatments. 
 
 
 Users can download the app after being prescribed by a physician and activate it using a pharmacist-issued activation code. The treatments (missions for users) are usually between eight and 12 weeks long, and patients can interact with physicians during or after completing therapy. In terms of partnerships, Click partnered with Magellan Health for clinical coaching and pharmacy benefits management in 2016. Additionally, the company has collaborated with Otsuka in a deal worth USD 302 million to develop and commercialize a PDT for the treatment of MDD, as well as a partnership with Boehringer Ingelheim to develop and commercialize a PDT to aid in the treatment of schizophrenia.
 
 
 Funding and financials
 
 
 In April 2022, the company secured USD 15 million in term loans from Silicon Valley Bank. The raised finances were partly used to pay back an existing loan facility with K2 HealthVentures (K2HV) in December 2020. K2HV is also an equity investor in the firm. The remaining financing, together with the company&rsquo;s equity capital, was earmarked to fund the development of its product pipeline. 
 
</div>

Pet ownership is at an all time high in the United States and the pet care economy is booming.

Pet Care Tech

<div>
 
 Otto (formerly 
 <a href="https://sp-edge.com/updates/21435">
 TeleVet)
 </a>
 is a web and mobile app solution provider that connects veterinary clinics with pet owners. Once set up through the 
 Otto
 platform, pet owners can send virtual consultations to clinics for review. Veterinarians can include virtual follow-up appointments as a part of their service offerings. As of June 2020, the 
 Otto
 platform was used by around 6,500 veterinarians in the US.
 
 
 The platform is offered on a SaaS bais for USD 99 per month for annual contracts and USD 129 per month for monthly contracts.
 
 
 Key customers and partnerships
 
 
 In March 2022, the company 
 <a href="https://sp-edge.com/updates/8932">
 partnered with Boehringer Ingelheim,
 </a>
 a pharmaceutical company, to expand Otto&rsquo;s services by becoming Boehringer Ingelheim&rsquo;s preferred veterinary health technology platform in the US. As part of the partnership, Boehringer Ingelheim invested an undisclosed amount in Otto; the company intends to use the funds and utilize Boehringer Ingelheim&rsquo;s commercial team for product development.
 
 
 Funding and financials
 
 
 In June 2020, the company raised USD 5 million in Series A funding led by Mercury Fund. The funds are expected to be used to accelerate the growth of the platform and the team. 
 
</div>

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

<div>
 
 NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company&rsquo;s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.
 
</div>

Ilara Health brings accurate and affordable diagnostics to rural Africans through miniature, AI-powered diagnostic devices that are integrated through a proprietary technology platform and distributed directly to primary care doctors.

Otto provides an integrated mobile app extension to existing veterinarian practice management systems. The Otto app allows two-way communication between clients and veterinary staff, enabling telemedicine, appointment scheduling, digital prescriptions and much more.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Proxygen is reshaping the druggable space. Their company harnesses technology and know-how to exploit this potential, thereby redefining the borders of the druggable target space. They developed rational discovery assays that, for the first time, enabled the identification and development of novel glue degraders at scale, putting them at the forefront of charting this unexplored chemical space.

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

Graybox Solutions is a growing company based in Montreal that develops software solutions for healthcare. Its mission is to provides advanced digital solutions that can help address the numerous healthcare challenges, reducing the payer burden associated with chronic care management.

PrometheraÂ® Biosciences is a biopharmaceutical company, spin-off of the UniversitÃ© Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.  PrometheraÂ® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.  PrometheraÂ® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Boehringer Ingelheim is a research-driven group of companies that focuses on researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life.

Boehringer Ingelheim International

Promoting the health, well-being, and ethical treatment of animals

Boehringer Ingelheim International

Featured Industries

EDGE Insights

Animal Therapeutics: Nurturing the health of our furry companions

Recent Updates

Phenomic AI and Boehringer Ingelheim collaborate to discover stroma-rich cancer targets

IBM and Boehringer Ingelheim partner to discover accelerated antibodies using AI-based FMs

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless